Literature DB >> 18626428

Intestinal flora, probiotics, and cirrhosis.

Ignacio Guerrero Hernández1, Aldo Torre Delgadillo, Florencia Vargas Vorackova, Misael Uribe.   

Abstract

Intestinal microflora constitutes a symbiotic ecosystem in permanent equilibrium, composed mainly of anaerobic bacteria. However, such equilibrium may be altered by daily conditions as drug use or pathologies interfering with intestinal physiology, generating an unfavorable environment for the organism. Besides, there are factors which may cause alterations in the intestinal wall, creating the conditions for translocation or permeation of substances or bacteria. In cirrhotic patients, there are many conditions that combine to alter the amount and populations of intestinal bacteria, as well as the functional capacity of the intestinal wall to prevent the permeation of substances and bacteria. Nowadays, numerous complications associated with cirrhosis have been identified, where such mechanisms could play an important role. There is evidence that some probiotic microorganisms could restore the microbiologic and immunologic equilibrium in the intestinal wall in cirrhotic patients and help in the treatment of complications due to cirrhosis. This article has the objective to review the interactions between intestinal flora, gut permeability, and the actual role of probiotics in the field of cirrhotic patients.

Entities:  

Mesh:

Year:  2008        PMID: 18626428

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  6 in total

Review 1.  Probiotics and gut health: a special focus on liver diseases.

Authors:  Silvia Wilson Gratz; Hannu Mykkanen; Hani S El-Nezami
Journal:  World J Gastroenterol       Date:  2010-01-28       Impact factor: 5.742

Review 2.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

3.  Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition.

Authors:  Ming Li; Lin Zhu; Ao Xie; Jieli Yuan
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

Review 4.  Gut microbiota and host metabolism in liver cirrhosis.

Authors:  Makoto Usami; Makoto Miyoshi; Hayato Yamashita
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

5.  Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis.

Authors:  A Horvath; B Leber; B Schmerboeck; M Tawdrous; G Zettel; A Hartl; T Madl; S Stryeck; D Fuchs; S Lemesch; P Douschan; E Krones; W Spindelboeck; F Durchschein; F Rainer; G Zollner; R E Stauber; P Fickert; P Stiegler; V Stadlbauer
Journal:  Aliment Pharmacol Ther       Date:  2016-09-04       Impact factor: 8.171

6.  The efficacy of parenteral nutrition (PN) and enteral nutrition (EN) supports in cirrhosis: A systematic review and network meta-analysis.

Authors:  Bin Yu; Jiting Wang
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.